menu search

SYRS / Syros Pharmaceuticals Is A Buy As New Trials Start

Tamibarotene Phase 2 AML data is expected in 2022. Positive trial AML or MDS data would lead to an application to the FDA in 2024. Read More
Posted: Nov 19 2021, 19:54
Author Name: Seeking Alpha
Views: 111957

SYRS News  

Syros Pharmaceuticals undergoes leadership shakeup, workforce reduction

By Proactive Investors
October 2, 2023

Syros Pharmaceuticals undergoes leadership shakeup, workforce reduction

Syros Pharmaceuticals shares dropped on Monday after a series of shakeups at the biotech company. The firm is saying goodbye to its CEO, Nancy Simonia more_horizontal

Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates

By Zacks Investment Research
August 8, 2023

Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates

Syros Pharmaceuticals, Inc. (SYRS) came out with a quarterly loss of $1.30 per share versus the Zacks Consensus Estimate of a loss of $1.11. This comp more_horizontal

Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates

By Zacks Investment Research
March 2, 2023

Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2022. more_horizontal

Syros: Multiple Shots On Goal In Blood Cancer Space

By Seeking Alpha
February 8, 2023

Syros: Multiple Shots On Goal In Blood Cancer Space

Final results from pivotal study SELECT-MDS-1, using Tamibarotene for the treatment of patients with newly diagnosed high-risk MDS that have RARA gene more_horizontal

Syros Pharmaceuticals A Buy Given Stock Price And Pipeline Potential (Rating Upgrade)

By Seeking Alpha
January 15, 2023

Syros Pharmaceuticals A Buy Given Stock Price And Pipeline Potential (Rating Upgrade)

Syros Pharmaceuticals is developing cancer therapies. Its most advanced potential therapy is tamibarotene for MDS. more_horizontal

Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies

By Benzinga
April 11, 2022

Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies

Syros Pharmaceuticals Inc (NASDAQ: SYRS) announced new preclinical data from its CDK12 inhibitor program, demonstrating robust anti-tumor activity more_horizontal

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 15, 2022

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2021 Results - Earnings Call Transcript

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2021 Results - Earnings Call Transcript more_horizontal

Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Tops Revenue Estimates

By Zacks Investment Research
March 15, 2022

Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Tops Revenue Estimates

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 4.55% and 38.09%, respectively, for the quarter ended December 2021. Do more_horizontal


Search within

Pages Search Results: